Women’s libido drug take two: bremelanotide
Bremelanotide, an experimental treatment for low or absent sexual desire in women, moved closer to the clinic Tuesday, following positive Phase 3 trial results.
Morning Read: Valeant slashes sales staff for women’s libido pill Addyi
Also, Gilead made a deal worth up to $1.2 billion to acquire drugs that treat NASH and liver cancer.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Even on CBS, Colbert takes aim at pharma, namely Addyi
Stephen Colbert, new host of "The Late Show with Stephen Colbert" on CBS — not the fake conservative pundit he played on "The Report" — can derive plenty of humor from needling the pharma industry.
From Denver’s new digital health center to a doctor’s take on Addyi approval: 5 must-read stories from MedCity News this week
A developer and a healthcare entrepreneur are planning a 300,000-square-foot digital health center in Denver, in a big to make the city the “digital health capital” of the U.S., and a doctor voices excitement over Addyi's approval.
Some doctors are speaking out about concerns with the FDA’s approval of Addyi
The approval of Addyi, or "female Viagra," has received a lot of hype, but is it worth it from a doctor's perspective?
Top sex doc on FDA approval of Addyi, women’s libido pill: ‘A nuclear bomb has exploded in women’s sexual health’
Dr. Irwin Goldstein, president of the Institute for Sexual Medicine, extolled the approval of Addyi, the first-ever drug approved to treat women's sexual dysfunction. He says it'll open the door for further conversation and research about women's health.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.